Back to search
FDAFDA · Food and drugs·Recall number D-0182-2023

Advil Liqui Gels, Solubilized ibuprofen capsules, 200mg, Pain Reliever Fever Reducer (NSAID), 200 liquid filled capsules, Distributed by: Pfizer, Madison, NJ 07940, UPC 3 0573 0169 49 3

Published February 1, 2023 · Recall initiated: December 6, 2022

Summary

FDA records drug Class I recall D-0182-2023, published February 1, 2023 and initiated December 6, 2022. Recalling firm: Glaxosmithkline Consumer Healthcare Holdings DBA Haleon; Status: Terminated; Reported quantity: 88,380 capsules; Lot: Lot: R94065, Exp 02/29/2024. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Glaxosmithkline Consumer Healthcare Holdings DBA Haleon
Distributor
Nationwide in the USA.
Lot
Lot: R94065, Exp 02/29/2024
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Advil Liqui Gels, Solubilized ibuprofen capsules, 200mg, Pain Reliever Fever Reducer (NSAID), 200 liquid filled capsules, Distributed by: Pfizer, Madison, NJ 07940, UPC 3 0573 0169 49 3 recalled?

Yes. FDA published recall D-0182-2023 on February 1, 2023. Reported hazard: Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back

What should I do if I have this product?

Voluntary: Firm initiated · Letter